Total buying$00 buys
MLYS
Mineralys Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 09/24 to 10/24.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$1.90M1 sells
Net open-market−$1.90MBuying minus selling
Active insiders3Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 20, 2026
Open-market transaction mix · 1 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 1 | 0 | $0 | $1.90M | -$1.90M |
| Oct 2026 | 0 | 0 | 4 | $0 | $0 | $0 |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (2)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- CJ-$1.9M
- PK+$0
- CL+$0
MLYS transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
MLYSMineralys Therapeutics, Inc. | Peterson KristineDIR | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
MLYSMineralys Therapeutics, Inc. | Peterson KristineDIR | A · grantSEC filing ↗ | $0View disclosure → | |
MLYSMineralys Therapeutics, Inc. | Coats LonnelDIR | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
MLYSMineralys Therapeutics, Inc. | Coats LonnelDIR | A · grantSEC filing ↗ | $0View disclosure → | |
MLYSMineralys Therapeutics, Inc. | Congleton JonCEO | S · sale10b5-1 detectedSEC filing ↗ | -$1.90MView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period5transactionstxns
- A · Grants / awards · dominant4 · 80%
- S · Open-market sells1 · 20%
Activity by reported role
A joint filing can contribute to multiple rolesDirector4
Chief executive officer1
Reported Holdings After
Separated by insider, security, and ownership type
Congleton JonCommon Stock · Direct
528,621Sep 30, 2026
Coats LonnelCommon Stock · Direct
12,400Oct 19, 2026
Coats LonnelStock Option · Direct
16,600Oct 19, 2026
Peterson KristineCommon Stock · Direct
12,400Oct 19, 2026
Peterson KristineStock Option · Direct
16,600Oct 19, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 24 → Oct 24
LessMore
Mineralys Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Mineralys Therapeutics, Inc.?
Peterson Kristine, COATS LONNEL, Congleton Jon.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Congleton Jon reported a sale on Sep 30, 2026 valued at $1.90M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $1,909,665.00. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.